State-of-the-art analysis for validating TNM staging system improvements using comprehensive statistical methods. This analysis provides pathologists with robust tools to evaluate whether a new staging system provides superior prognostic discrimination compared to existing systems.
Value
A comprehensive staging validation analysis with statistical comparisons, clinical interpretation, and advanced visualizations
Details
This comprehensive staging validation analysis includes:
Core Migration Analysis:
Migration matrices with detailed statistics
Stage distribution comparisons
Will Rogers phenomenon detection
Upstaging and downstaging quantification
Advanced Discrimination Metrics:
Harrell's C-index with confidence intervals
Net Reclassification Improvement (NRI)
Integrated Discrimination Improvement (IDI)
Time-dependent ROC analysis
Likelihood ratio tests for nested models
Clinical Utility Assessment:
Decision Curve Analysis (DCA)
Net benefit calculations
Clinical significance thresholds
Cancer-type specific interpretations
Validation Framework:
Bootstrap validation with optimism correction
Cross-validation options
Stability assessment
Internal validation metrics
Advanced Visualizations:
Migration heatmaps with flow statistics
Time-dependent ROC curves
Calibration plots
Decision curves
Forest plots with confidence intervals
PHASE 1 ENHANCEMENTS - Evidence-Based Assessment Framework:
Will Rogers Evidence Assessment: Multi-criteria evaluation framework
Migration Pattern Analysis: Advanced flow statistics and retention rates
Survival Pattern Validation: Upstaged patient survival similarity analysis
Biological Consistency Checks: Risk factor profile assessments
Landmark Analysis Integration: Time-based cutoff discrimination analysis
Clinical Decision Support: Evidence-based implementation recommendations
Traffic Light Assessment: PASS/BORDERLINE/CONCERN/FAIL evidence grading
Enhanced Heatmap Analytics: Major flow identification and net migration analysis
Clinical Applications
TNM staging system validation (7th to 8th edition transitions)
AJCC staging improvements
Institution-specific staging modifications
Multi-institutional staging harmonization
Biomarker-enhanced staging systems
Statistical Methods
The analysis implements state-of-the-art methods for staging validation:
NRI: Quantifies net improvement in risk classification
IDI: Measures integrated discrimination improvement
C-index: Harrell's concordance with bootstrap confidence intervals
DCA: Clinical utility across decision thresholds
Bootstrap: Internal validation with bias correction
Clinical Decision Framework
Results include comprehensive guidance for staging system adoption:
Statistical significance vs. clinical importance
Effect size interpretation (small, medium, large improvements)
Sample size adequacy assessment
Recommendation confidence levels
Implementation considerations
Data Requirements
Sample Size: Minimum 30 patients (100+ recommended)
Follow-up: Adequate survival time for meaningful analysis
Staging: Both old and new staging variables with 2+ levels
Events: Binary event indicator (0/1) or factor with specified level
Data Quality: Complete case analysis (missing values removed)
Troubleshooting
"TRUE/FALSE error": Check for missing values in staging or survival variables
"Not atomic error": Disable individual tables to isolate problematic components
Model fitting errors: Ensure adequate sample size and event rate (5-95%)
Stage level errors: Verify staging variables have multiple distinct levels
See also
concordance
for C-index calculations,
ggsurvplot
for survival visualizations
Super classes
jmvcore::Analysis
-> ClinicoPath::stagemigrationBase
-> stagemigrationClass
Methods
Inherited methods
jmvcore::Analysis$.createImage()
jmvcore::Analysis$.createImages()
jmvcore::Analysis$.createPlotObject()
jmvcore::Analysis$.load()
jmvcore::Analysis$.render()
jmvcore::Analysis$.save()
jmvcore::Analysis$.savePart()
jmvcore::Analysis$.setCheckpoint()
jmvcore::Analysis$.setParent()
jmvcore::Analysis$.setReadDatasetHeaderSource()
jmvcore::Analysis$.setReadDatasetSource()
jmvcore::Analysis$.setResourcesPathSource()
jmvcore::Analysis$.setStatePathSource()
jmvcore::Analysis$addAddon()
jmvcore::Analysis$asProtoBuf()
jmvcore::Analysis$asSource()
jmvcore::Analysis$check()
jmvcore::Analysis$init()
jmvcore::Analysis$optionsChangedHandler()
jmvcore::Analysis$postInit()
jmvcore::Analysis$print()
jmvcore::Analysis$readDataset()
jmvcore::Analysis$run()
jmvcore::Analysis$serialize()
jmvcore::Analysis$setError()
jmvcore::Analysis$setStatus()
jmvcore::Analysis$translate()
ClinicoPath::stagemigrationBase$initialize()
Examples
if (FALSE) { # \dontrun{
# Basic staging comparison
stagemigration(
data = cancer_data,
oldStage = "old_stage",
newStage = "new_stage",
survivalTime = "survival_months",
event = "outcome",
eventLevel = "DEAD",
analysisType = "basic"
)
# Comprehensive analysis with all options
stagemigration(
data = lung_cancer_cohort,
oldStage = "tnm7_stage",
newStage = "tnm8_stage",
survivalTime = "os_months",
event = "death",
eventLevel = "dead",
analysisType = "comprehensive",
calculateNRI = TRUE,
performBootstrap = TRUE,
bootstrapReps = 1000
)
# PHASE 1 ENHANCED: Evidence-based Will Rogers assessment
stagemigration(
data = pancreatic_cohort,
oldStage = "T_AJCC8",
newStage = "T_modified",
survivalTime = "overall_survival_months",
event = "death_status",
eventLevel = "Dead",
analysisType = "publication",
advancedMigrationAnalysis = TRUE,
showMigrationHeatmap = TRUE,
cancerType = "other",
showExplanations = TRUE
)
# Phase 1 Enhanced with landmark analysis for lung cancer
stagemigration(
data = lung_staging_data,
oldStage = "stage_7th_edition",
newStage = "stage_8th_edition",
survivalTime = "survival_months",
event = "vital_status",
eventLevel = "deceased",
analysisType = "comprehensive",
advancedMigrationAnalysis = TRUE,
cancerType = "lung", # Uses lung-specific landmark times: 3,6,12,24 months
showWillRogersVisualization = TRUE,
showMigrationSurvivalComparison = TRUE
)
} # }